InnoCare Pharma Ltd banner

InnoCare Pharma Ltd
SSE:688428

Watchlist Manager
InnoCare Pharma Ltd Logo
InnoCare Pharma Ltd
SSE:688428
Watchlist
Price: 24.2 CNY -0.74% Market Closed
Market Cap: ¥20.4B

Wall Street
Price Targets

Price Targets Summary
InnoCare Pharma Ltd

Wall Street analysts forecast InnoCare Pharma Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 39.54 CNY with a low forecast of 34.34 CNY and a high forecast of 49.64 CNY.

Lowest
Price Target
34.34 CNY
42% Upside
Average
Price Target
39.54 CNY
63% Upside
Highest
Price Target
49.64 CNY
105% Upside
InnoCare Pharma Ltd Competitors:
Price Targets
PTGX
Protagonist Therapeutics Inc
24% Upside
ELAN
Elanco Animal Health Inc
8% Upside
CYBR
Cyberark Software Ltd
21% Upside

Revenue
Forecast

-1% / Year
Past Growth
35% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
-1% / Year
Past Growth
35% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

For the last 3 years the compound annual growth rate for InnoCare Pharma Ltd's revenue is -1%. The projected CAGR for the next 4 years is 35%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is InnoCare Pharma Ltd's stock price target?
Price Target
39.54 CNY

According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 39.54 CNY with a low forecast of 34.34 CNY and a high forecast of 49.64 CNY.

What is InnoCare Pharma Ltd's Revenue forecast?
Projected CAGR
35%

For the last 3 years the compound annual growth rate for InnoCare Pharma Ltd's revenue is -1%. The projected CAGR for the next 4 years is 35%.

Back to Top